211 Spanish Registry of Erythropoietic Stimulating Agents Study: The Largest Retrospective Study of Esas for the Treatment of Anemia in Lower Risk MDS Patients

Díez-Campelo, Maria; Lorenzo, José Ignacio; Benlloch, Luis; Lopez-Pavia, M.; Such, Esperanza; Bernal, Teresa; Luño, Elisa; Dávila, Julio C.; Ramos, Frederick; Calabuig, Marisa; Pomares, Helena; González, Bernardo; Merchán, Brayan; Barranco, Edgardo; Tello, Reyes Sancho; Callejas, Marta; Requena, Manuel; Jiménez, Manuel Jesús Romero; Pedreño, María; Vicente, AB; Medina, Antonio Ramos‐De la; Campeny, A.; Sansa, Montse Cortes; Pedro, Carme; Falantes, José; Arilla, M.J.; Bárez, Abelardo; Garcia, Raphael Moura; Arcos, María José; Gómez, Victoria; Muñoz, Carmen Paterson; Cerveró, Carlos; Casaño, Javier; Paz, Raquel de; Amigo, Luz; Insunza, Andrés; Muñoz, J; Cedena, María Teresa; Gómez, Marisa I.; Font, Patricia; Campo, Raquel; Lago, C. Fernández; Hurtado, José Antonio; Latorre, Melissa; Casado, Asunción Mora; Vahi, María; Sanz, G.F.; Cañizo, M.C.

doi:10.1016/s0145-2126(15)30212-5

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, diagnosis may be more complicated due to the absence of other cytopenias that otherwise might help identify MDS. 17 In five patients, our laboratory-based approach facilitated the di- 22,23 The estimated 3-year OS in the MDS patients we diagnosed was 71% and was significantly higher among lower-risk (IPSS-R ≤ 3.5) than higher-risk patients (IPSS-R > 3.5; 100% vs 0%; P < .001), consistent with previous reports. 16,24,25 Recently, somatic mutations have been described in >80%-90%…”

Section: Discussionsupporting

confidence: 87%

“…17 In five patients, our laboratory-based approach facilitated the diagnosis of anemia before it became symptomatic, allowing treatment before it became severe (ie, requiring red blood cell transfusions), potentially improving quality of life and reducing the number of diagnosisrelated hospital visits. Median time from diagnosis to treatment in our study was 45 days (range, 21-52 days) for lower-risk patients, while in other studies of lower-risk newly diagnosed MDS patients, it was 130 days (range, 60-450 days; ARCADE study) and 92 days (range, 1-5683 days; SPRESAS study [Spanish registry of ESAs in anemic lowrisk MDS patients]) 22,23 The estimated 3-year OS in the MDS patients we diagnosed was 71% and was significantly higher among lower-risk (IPSS-R ≤ 3.5) than higher-risk patients (IPSS-R > 3.5; 100% vs 0%; P < .001), consistent with previous reports. 16,24,25 Recently, somatic mutations have been described in >80%-90% of patients with MDS.…”

Section: Recent Data From the Us Surveillance Epidemiology And Endcontrasting

confidence: 51%

See 1 more Smart Citation

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

Bastida

López‐Godino

Vicente-Sánchez

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction Diagnosis of myelodysplastic syndromes (MDSs) when anemia is the only abnormality can be complicated. The aim of our study was to investigate the primary causes of anemia and/or macrocytosis of uncertain etiology. Methods We conducted a multicenter, prospective study over 4 months in three hematology laboratories. In step 1, we used an automated informatics system to screen 137 453 hemograms for cases of anemia and/or macrocytosis (n = 2702). In step 2, we excluded all patients whose anemia appeared to be due to a known cause. This left 290 patients had anemia of uncertain etiology. In step 3, we conducted further investigations, including a peripheral blood smear, and analysis of iron, vitamin B12, folate, and thyroid hormone levels. Results A differential diagnosis was obtained in 139 patients (48%). The primary causes of anemia were iron deficiency (n = 59) and megaloblastic anemia (n = 39). In total, 25 hematologic disorders were diagnosed, including 14 patients with MDS (56%). The median age of MDS patients was 80 years, 12 had anemia as an isolated cytopenia, and most (n = 10) had lower‐risk disease (IPSS‐R ≤ 3.5). SF3B1 mutations were most frequent (n = 6) and correlated with the presence of ring sideroblasts (100%) and associated with better prognosis (P = 0.001). Conclusions Our prospective, four‐step approach is an efficient and logical strategy to facilitate the diagnosis of MDS on the basis of unexplained anemia and/or macrocytosis, and may allow the early diagnosis of the most serious causes of anemia. Molecular analysis of genes related to MDS could be a promising diagnostic and prognostic approach.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Recent Data From the Us Surveillance Epidemiology And Endcontrasting

confidence: 51%

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

Bastida

López‐Godino

Vicente-Sánchez

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

et al. 2017

View full text Add to dashboard Cite

The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 weeks of subcutaneous darbepoetin alfa 500 μg or placebo every 3 weeks (Q3W), followed by 48 weeks of open-label darbepoetin alfa. A total of 147 patients were randomized, with median hemoglobin of 9.3 (Q1:8.8, Q3:9.7) g/dl and median baseline serum EPO of 69 (Q1:36, Q3:158) mU/ml. Transfusion incidence from weeks 5–24 was significantly lower with darbepoetin alfa versus placebo (36.1% (35/97) versus 59.2% (29/49), P=0.008) and erythroid response rates increased significantly with darbepoetin alfa (14.7% (11/75 evaluable) versus 0% (0/35 evaluable), P=0.016). In the 48-week open-label period, dose frequency increased from Q3W to Q2W in 81% (102/126) of patients; this was associated with a higher hematologic improvement–erythroid response rate (34.7% (34/98)). Safety results were consistent with a previous darbepoetin alfa phase 2 MDS trial. In conclusion, 24 weeks of darbepoetin alfa Q3W significantly reduced transfusions and increased rates of erythroid response with no new safety signals in lower-risk MDS (registered as EudraCT#2009-016522-14 and NCT#01362140).

show abstract

211 Spanish Registry of Erythropoietic Stimulating Agents Study: The Largest Retrospective Study of Esas for the Treatment of Anemia in Lower Risk MDS Patients

Cited by 2 publications

References 0 publications

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Contact Info

Product

Resources

About